Skip to main content
. 2019 Oct 22;10(58):6111–6123. doi: 10.18632/oncotarget.27222

Figure 2. Antitumor efficacy of gilteritinib and quizartinib.

Figure 2

(A) FL expression was detected in FL-expressing or mock MOLM-13 cells. FL-expressing or mock MOLM-13 cells were subjected to western blotting analysis using the indicated antibodies. (B) Plasma FL concentrations were determined on day 22, and data are shown as mean ± SEM (n = 5). Tumor volume was measured on day 18, and data are shown as mean ± SEM (n = 6). (C) Mice engrafted with FL-expressing or mock MOLM-13 cells were orally administered gilteritinib or quizartinib at 30 mg/kg or 3 mg/kg, respectively. Tumor volume was measured, and data are shown as mean ± SEM (n = 10). Tumor volume on day 11 was compared between the gilteritinib-treated group and quizartinib-treated group using Student’s t-test. ** P < 0.01. Abbreviations: FL, FLT3 ligand; ND, not detected; N. S., not significantly different.